title: Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima.
abstract: The 20th Hiroshima Cancer seminar focused upon breast cancer research and treatment particularly on the mechanism of tumorigenesis and drug resistance and development of novel therapeutics. Several molecules such as retinoblastoma and p16 were raised as key factors in tumorigenesis and invasiveness. Estrogen-related pathways seem to be closely involved in the process. For the tumor lacking hormone receptor and human epidermal growth factor 2, some other mechanisms could be responsible. It seems that MicroRNA 22 directing some putative targets such as SIRT1, Sp1 and CDK6 plays a crucial role in breast tumor growth and metastasis. In addition, ribophorin and the associated molecules might be engaged in breast cancer stemness. Obviously, these molecules provide potential for therapeutic targets. It was also discussed about new drug development such as anti-human epidermal growth factor 2 therapy, anti-angiogenesis, pro-tumor aspects of anti-cancer therapy and application of circulating markers for monitoring, imaging and health-care system. Furthermore, we discussed risk factors, prevention and screening to reduce invasive cancers as well. Throughout the conference, panelists and attendee indicated the importance of translational research and biomarker exploration in order to realize efficient and individualized therapy for breast cancer.
authors.affiliation: Hiroshima Cancer Seminar Foundation, 3-8-6 Sendamachi, Naka-ku, Hiroshima 730-0052, Japan.
authors.forename: Masakazu
authors.initials: M
authors.lastname: Toi
authors.forename: Wataru
authors.initials: W
authors.lastname: Yasui
authors.forename: Hisao
authors.initials: H
authors.lastname: Ito
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tahara
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003362:Cost-Benefit Analysis; D051361:Cyclin-Dependent Kinase 6 / Q000378:metabolism; D019941:Cyclin-Dependent Kinase Inhibitor p16; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D004967:Estrogens / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D006602:Hexosyltransferases; D006801:Humans; D019458:Insurance Coverage; D007391:International Cooperation; D008565:Membrane Proteins / Q000378:metabolism; D035683:MicroRNAs / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000379:methods; D009363:Neoplasm Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D049268:Positron-Emission Tomography / Q000379:methods; D046988:Proteasome Endopeptidase Complex; D061988:Proteasome Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D056564:Sirtuin 1 / Q000378:metabolism; D014495:Universities
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D051361:Cyclin-Dependent Kinase 6; D019941:Cyclin-Dependent Kinase Inhibitor p16; D004967:Estrogens; D019788:Fluorodeoxyglucose F18; D006602:Hexosyltransferases; D008565:Membrane Proteins; D035683:MicroRNAs; D009363:Neoplasm Proteins; D046988:Proteasome Endopeptidase Complex; D061988:Proteasome Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D056564:Sirtuin 1; C000614131:CDKN2A protein, human; C548375:MIRN22 microRNA, human; C034241:ribophorin; C517590:RPN2 protein, human; C508053:ERBB2 protein, human; C495911:CDK6 protein, human; C447939:SIRT1 protein, human